INNOVOTEX raises strategic financing for NOVO-111 development

INNOVOTEX closed a strategic financing led by Bull Life Sciences to fund IND-enabling work for its lead cancer candidate, NOVO-111. The company plans to use the capital to advance manufacturing, toxicology and regulatory studies as it moves toward an IND submission.

Why it matters: - The financing gives INNOVOTEX the capital to push NOVO-111 through the next regulatory milestones in oncology. - The deal also adds a long-term lead investor as the company seeks future pharmaceutical partnerships. - INNOVOTEX is developing Macrocycle Drug Conjugates aimed at improving the therapeutic index of established cancer therapies.

What happened: - INNOVOTEX closed a strategic financing to support IND-enabling development of NOVO-111, its lead oncology candidate. - Bull Life Sciences led the financing. - The company announced the deal on Aug. 11, 2026, in Austin, Texas. - CEO Krystle Karoscik said the financing validates INNOVOTEX's scientific approach and development strategy.

The details: - NOVO-111 is designed to improve tumor-selective delivery of oxaliplatin while reducing systemic exposure. - The goal is to improve efficacy and reduce dose-limiting toxicities associated with conventional platinum chemotherapy. - INNOVOTEX plans to use a 505(b)(2) pathway to expedite development toward an IND submission. - The U.S. Food and Drug Administration confirmed that regulatory approach. - Financing proceeds will support manufacturing scale-up, GLP toxicology, pharmacology and other regulatory-enabling studies. - INNOVOTEX expects those activities to position NOVO-111 for clinical evaluation. - The company said the work should create multiple value-inflection points in the coming months. - Bull Life Sciences Executive Chairman and CEO Danny Stapleton said the firm is committed to backing management teams pursuing transformative innovation.

Between the lines: - The financing lands as biotech venture capital has rebounded in 2026, but capital remains selective. - Investors are concentrating on companies with differentiated science and clear development paths. - INNOVOTEX is trying to position its MDC platform as a way to extend the value of clinically validated oncology drugs. - The company is also looking to deepen partnering discussions with global pharmaceutical companies seeking external innovation. - Demand remains strong for preclinical and early-stage oncology assets that can help refill pharma pipelines.

What's next: - INNOVOTEX will move NOVO-111 through IND-enabling studies. - The company expects to advance toward an IND submission after manufacturing, toxicology and pharmacology work is complete. - INNOVOTEX also plans to continue discussions with potential pharmaceutical partners as the program advances. - Success in the next few months could create new catalysts for the company and its investors. - The company’s broader MDC platform will remain part of its pitch to future partners and investors.